A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
The management of chronic hepatitis C (CHC) is a rapidly evolving field. New treatment paradigms are emerging due to an improved understanding of the host-viral interaction and the recent development of novel anti-viral therapies. Nevertheless, combination therapy with pegylated interferon (PEG-IFN) and ribarivin (RBV) remains the cornerstone of the treatment of CHC and will likely remain so for the foreseeable future. Over the past decade treatment regimens involving peginterferon plusdoi:10.4137/cmt.s4015 fatcat:jpmowswowjfgvj4uusgvlwvhpu